Transthyretin Amyloidosis Treatment Market Analysis & Forecast: 2026-2033

Transthyretin Amyloidosis Treatment Market Size and Share Analysis - 2026 To 2033

The global transthyretin amyloidosis treatment market size is projected to grow from USD 1,217.6 Mn in 2026 to USD 26,647.0 Mn by 2033, registering a compound annual growth rate (CAGR) of 55.4% during the forecast period (2026–2033). The substantial growth is expected to be driven by rising awareness and diagnosis of transthyretin amyloidosis, growing adoption of disease-modifying therapies, increasing investments in rare disease research, and continued advancements in precision medicine are expected to drive market growth.

Key Takeaways from the Transthyretin Amyloidosis Treatment Market Report

• Tafamidis (Vyndaqel) is projected to dominate the market with an estimated share of 58.7% in 2026, owing to its first mover advantage, high clinical efficacy, and wide regulatory approvals for transthyretin amyloidosis. Tafamidis is the first-in-class medicine and is the first FDA-approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis has shown a considerable reduction in all-cause mortality and cardiovascular-related hospitalizations, which supports its uptake in the major markets.
• Hereditary Transthyretin Amyloidosis is estimated to have the highest market share of 68.4% in 2026, due to rising genetic testing, rising disease awareness, and rising availability of targeted medicines. Published epidemiological studies showed that the diagnosed prevalent population of hereditary transthyretin amyloidosis (hATTR) was more than 11,000 cases across key developed markets, underlining the large treatment demand for hereditary variants of the disease.
• Hospital Pharmacies are expected to hold the largest market share of 52.3% until 2026 due to specialized nature of transthyretin amyloidosis therapy, need for physician supervision and high cost of novel medicines. Diagnosis, start of treatment, and patient monitoring for ATTR-related illnesses are mostly performed at hospital-based treatment centers.
• North America is projected to have the highest share of the worldwide transthyretin amyloidosis treatment market in 2026, at an estimated 47.8%, driven by high diagnosis rates, strong access to innovative medicines, and a supportive regulatory environment. The 15-year Transthyretin Amyloidosis Outcomes Survey (THAOS) demonstrated that 56.2% of patients in North America were diagnosed with wild-type ATTR (ATTRwt) amyloidosis, indicating the sizeable treatment pool for ATTR cardiomyopathy therapeutics in North America.

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Tafamidis (Vyndaqel) Acquiring the Largest Market Share?

Tafamidis (Vyndaqel) is expected to account for 58.7% of the total revenue share of the transthyretin amyloidosis therapy market in 2026. The market is driven by first-mover advantage, strong clinical data and broad regulatory approvals for transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis was the first drug approved especially for ATTR-CM and has become the standard of therapy in many developed markets.

The landmark ATTR-ACT trial demonstrated a therapeutic benefit with tafamidis in patients with transthyretin amyloid cardiomyopathy, including a reduction in all-cause death by 30% and cardiovascular-related hospitalizations by 32% compared to placebo. These results have led to a huge rise in physician confidence and global uptake of the treatment.

In November 2025, Pfizer announced continued expansion of Vyndaqel and Vyndamax patient support initiatives aimed at improving treatment accessibility and disease awareness among ATTR patients.

Which Disease Type Segment Dominates the Market? 

To learn more about this report, Request Free Sample

Hereditary Transthyretin Amyloidosis (hATTR) is expected to dominate the market during the forecast period with a share of about 68.4% in 2026 due to the growing genetic screening programs, growing awareness for inherited amyloid disorders, and growing access to targeted therapies such as patisiran, vutrisiran, and eplontersen.

Healthcare practitioners are becoming more aware and breakthroughs in molecular diagnostics are helping to intervene earlier. This is especially essential because hereditary ATTR amyloidosis is a progressive illness that can include numerous organ systems including the heart and peripheral nerves.

In June 2025, AstraZeneca Alexion Rare Disease announced continued investment in rare disease diagnostic initiatives and patient identification programs aimed at improving access to genetic testing for hereditary ATTR amyloidosis.

Which Distribution Channel Segment Dominates the Market?

Hospital Pharmacies are projected to account for major market share with 52.3% in 2026, on account of the specialized nature of transthyretin amyloidosis treatment, requirement for interdisciplinary disease management, and high acquisition cost of innovative therapies.

ATTR amyloidosis patients often require coordinated care and long-term follow-up from cardiologists, neurologists, genetic counselors, and rare disease specialists. Thus, treatment initiation and ongoing management are often coordinated through hospital-based centers of excellence and specialty clinics. Hospital pharmacists play a crucial role in the distribution of sophisticated therapies and help ensure patient adherence through established monitoring systems.

According to the Amyloidosis Research Consortium, ATTR amyloidosis remains a complex multisystem disease requiring coordinated care among multiple specialties, reinforcing the importance of hospital-centered treatment pathways.

Market Drivers

Continuous Regulatory Approvals and Therapeutic Innovations are Transforming ATTR Treatment

The transthyretin amyloidosis therapy landscape is rapidly expanding with the advent of innovative gene-silencing therapies, TTR stabilizers and next-generation disease-modifying medicines. Pharmaceutical companies are actively developing therapies that target the underlying cause of ATTR amyloidosis rather than only managing symptoms. These advances are translating into improved survival, slower disease progression and improved quality of life for patients with hereditary and wild-type ATTR amyloidosis.

In November 2024, the U.S. Food and Drug Administration approved ATTRUBY (acoramidis) for the treatment of ATTR cardiomyopathy, adding another important therapeutic option to the market.

Current Events and Their Impact on the Transthyretin Amyloidosis Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Transthyretin Amyloidosis Treatment Market Trends

• Gene-silencing therapies gain traction, with drugs such as vutrisiran, eplontersen, and patisiran expanding treatment options beyond symptom management.
• Earlier diagnosis boosts treatment demand.
• New drug approvals expand the market. The U.S. FDA approved ATTRUBY (acoramidis) in 2024 based on a Phase III study involving 632 patients.
• Patient registries improve disease awareness. The THAOS Registry has enrolled 6,000+ patients across 20+ countries, supporting earlier diagnosis and research.
• Precision medicine investment rises, with growing development of RNA-based, antisense, and gene-editing therapies for ATTR amyloidosis.

Regional Insights 

To learn more about this report, Request Free Sample

North America Dominates Owing to Strong ATTR Diagnosis Rates and Rapid Adoption of Novel Therapies

North America is projected to hold the 47.8% share of the worldwide transthyretin amyloidosis treatment market in 2026, owing to the presence of modern healthcare infrastructure, high availability of genetic testing, favorable reimbursement policies and swift adoption of new medicines. The region has emerged as the top market for ATTR treatment owing to the increased diagnosis rates and early access to FDA-approved medicines along with expanding awareness among cardiologists and neurologists.

In August 2025, BridgeBio announced long-term ATTRibute-CM extension data showing that acoramidis achieved a 44% reduction in cardiovascular mortality risk and a 46% reduction in the risk of cardiovascular mortality or first cardiovascular hospitalization through Month 42, reinforcing physician confidence in disease-modifying ATTR therapies.

Asia Pacific Transthyretin Amyloidosis Treatment Market Trends

The Asia Pacific region is expected to be the fastest-growing market during 2026–2033 with an anticipated CAGR of 59.1% owing to increasing awareness of rare diseases, surging healthcare expenditure, developing genetic testing capabilities, and increased access to innovative ATTR medicines.

In addition, pharmaceutical companies are increasing their footprint beyond Asia Pacific via clinical trials, patient identification programs, and regulatory clearances. For instance, Alnylam Pharmaceuticals and AstraZeneca Alexion have expanded rare disease programs throughout Asian countries to boost access to ATTR medicines and genetic diagnostics. These activities are projected to drive diagnostic rates and increase market growth during the forecast period.

Growing Adoption of Novel ATTR Therapies is Accelerating the Transthyretin Amyloidosis Treatment Market in the United States

The United States transthyretin amyloidosis treatment market is witnessing robust expansion, propelled by heightened illness awareness, enhanced diagnostic capabilities, and swift acceptance of disease-modifying treatments. The U.S. is the largest ATTR treatment market in the world, due to its advanced healthcare infrastructure, advantageous reimbursement landscape, and a strong presence of pharmaceutical companies that specialize in rare diseases.

Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration expanded the orphan drug designation for patisiran to include the treatment of Transthyretin Amyloidosis, broadening its previous designation for familial amyloidotic polyneuropathy.

Japan Transthyretin Amyloidosis Treatment Market Trends

The Japan transthyretin amyloidosis treatment market is anticipated to witness considerable growth during the projected period due to the presence of one of the oldest populations in the world, high awareness of uncommon diseases, and well-established hereditary ATTR amyloidosis screening programs. Japan has historically been one of the most important countries for ATTR research with endemic hereditary ATTR mutations and a wealth of clinical experience in disease care.

According to the National Library of Medicine, Japan remains one of the countries with the highest documented concentrations of hereditary ATTR amyloidosis patients, making it a key market for targeted therapies and genetic testing services.

Who are the Major Companies in Transthyretin Amyloidosis Treatment Industry

Some of the major key players in Transthyretin Amyloidosis Treatment are Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Key News

• In March 2025, Alnylam announced that the U.S. FDA approved AMVUTTRA (vutrisiran) for ATTR-CM, expanding its indication beyond hereditary ATTR polyneuropathy. The approval was supported by the HELIOS-B Phase III study.
• In May 2025, Pfizer reported continued global expansion of VYNDAQEL/VYNDAMAX (tafamidis) and presented additional real-world evidence supporting long-term survival benefits in ATTR-CM patients at major cardiology congresses.

Market Report Scope 

Analyst Opinion

• The transthyretin amyloidosis (ATTR) therapeutic market is driven by a huge unmet medical need, rather for elective demand. ATTR amyloidosis is a progressive and life-threatening disease that is frequently underdiagnosed, leaving significant room for enhanced screening and treatment uptake.
• Improved diagnostic technologies are broadening the target patient population. According to research from the U.S. National Library of Medicine, about 13% of patients with heart failure with preserved ejection fraction (HFpEF) and increasing thickness of the heart’s ventricle wall have ATTR cardiomyopathy, meaning that a large number of people globally remain undetected.
• The market is experiencing a significant transition towards disease modifying treatments. Gene-silencing medications, transthyretin stabilizers and next generation therapeutics are improving survival outcomes and decreasing disease progression, expanding treatment beyond symptom management and offering long-term growth potential.
• Market expansion supported by recent regulatory clearances. The approvals of ATTRUBY (acoramidis), AMVUTTRA (vutrisiran), and WAINUA (eplontersen) have greatly increased therapy alternatives, boosted physician confidence, and improved the commercial picture for the ATTR treatment market.
• Despite significant development prospects, high treatment costs and delayed diagnosis remain major hurdles. Companies who can enhance patient identification, broaden reimbursement coverage and show long-term clinical benefit are expected to acquire a competitive edge in the comings years.

Market Segmentation

• By Drug Type (Revenue, USD Mn, 2021-2033)
  • Tafamidis (Vyndaqel)
  •  Patisiran (ONPATTRO)
  •  Inotersen (TEGSEDI)
  •  Others
• By Disease Type (Revenue, USD Mn, 2021-2033)
  • Hereditary Transthyretin Amyloidosis
    • Polyneuropathy
    • Cardiomyopathy
    • Mixed Type
  • Wild Type Amyloidosis
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Cardiologists
• Neurologists
• Amyloidosis specialists
• Rare disease treatment experts
• Hospital pharmacists
• Specialty pharmacy managers
• Genetic counselors
• Pharmaceutical company executives
• Key opinion leaders (KOLs) in amyloidosis treatment

Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• National Institutes of Health (NIH)
• National Library of Medicine (NLM)
• ClinicalTrials.gov
• Centers for Disease Control and Prevention (CDC)
• European Medicines Agency (EMA)
• Organisation for Economic Co-operation and Development (OECD)

Magazines

• Rare Disease Advisor
• Pharmaceutical Executive
• BioPharma Dive
• Drug Discovery World
• PharmaVoice

Journals

• Journal of the American College of Cardiology (JACC)
• Circulation
• The New England Journal of Medicine (NEJM)
• Orphanet Journal of Rare Diseases
• Amyloid: The International Journal of Experimental and Clinical Investigation
• European Heart Journal
• Journal of Cardiac Failure

Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• Reuters Health
• Bloomberg

Associations

• Amyloidosis Research Consortium (ARC)
• International Society of Amyloidosis (ISA)
• American Heart Association (AHA)
• Heart Failure Society of America (HFSA)
• National Organization for Rare Disorders (NORD)
• European Society of Cardiology (ESC)

Public Domain Sources

• Company Annual Reports and Investor Presentations
• FDA Drug Approval Announcements
• EMA Regulatory Updates
• Government Health Ministry Publications
• Clinical Trial Registries such as ClinicalTrials.gov
• THAOS (Transthyretin Amyloidosis Outcomes Survey) Registry Publications
• Peer-Reviewed Scientific Publications

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years